Heart failure learning module 2: diagnosis

Released1 November 2017     Expires: 01 November 2019      Programme:

Exercise capacity testing

Assessing functional and exercise capacity is an important part of the clinical assessment of patients with heart failure.

The NYHA classification is a widely used tool to grade the severity of a patient’s symptoms. However, reproducibility of NYHA class is low, with low validity and reproducibility.9,10 Objective measures such as the 6-minute walk test (6MWT) give more reliable information regarding a patients’ exercise capacity, although are susceptible to a ‘learning effect’.

Screen shot 2014-02-21 at 14.33.52

The 6MWT

The 6MWT measures the distance walked during six minutes on a hard, flat surface. The patient goes at their own pace and rests as needed. It is easy to perform in the corridor of a ward or outpatient clinic without the need for equipment: the recommended corridor length is 30 metres.11 In healthy adults, the normal 6MWT distance is between 400-700m.In patients with heart failure, 6MWT distance <300m is associated with worse cardiovascular outcomes.12


Incremental ETTs

While the 6MWT is a test of aerobic endurance, incremental exercise tests such as the Bruce treadmill test or incremental shuttle walk test, are a better indicator of maximal aerobic performance. In patients without significant limitation, incremental exercise tests may be preferable to the 6MWT for assessing the exercise capacity of patients with heart failure.

Gas exchange analysis using the peak oxygen consumption (peak VO2)
An incremental protocol can be coupled to the measurement of metabolic gas exchange to derive objective measures of exercise capacity such as the anaerobic threshold, peak oxygen consumption and the ventilatory response to exercise. Such tests can be helpful in differentiating dyspnoea of cardiac or respiratory origin, and are often used as part of assessment for heart transplant.

Normal exercise capacity in a patient not receiving treatment effectively excludes the diagnosis of symptomatic heart failure. However, there is a poor correlation between exercise capacity and resting haemodynamic measures, including ejection fraction.

Haemodynamic studies

Haemodynamic assessments of patients with heart failure can give information on a patient’s fluid status. They are usually invasive, and continuous monitoring techniques in ambulatory patients are not routinely available.

Click here to read more

Implantable devices for continuous measurement of pulmonary artery pressure (and even of left atrial pressure) have been developed. Pulmonary artery pressure increases in patients with chronic stable heart failure as they decompensate before the onset of symptoms. Some studies have shown that an implantable device that measures pulmonary artery pressure results in patients receiving more aggressive medical therapy and reduces hospital admissions with heart failure.13,14

Measuring cardiac output with thermodilution together with direct measurement of intra-cardiac pressures can occasionally be useful in patients hospitalised with severe or refractory heart failure.


All rights reserved. No part of this programme may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publishers, Medinews (Cardiology) Limited.

It shall not, by way of trade or otherwise, be lent, re-sold, hired or otherwise circulated without the publisher’s prior consent.

Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs becomes necessary. The editors/authors/contributors and the publishers have taken care to ensure that the information given in this text is accurate and up to date. Readers are strongly advised to confirm that the information, especially with regard to drug usage, complies with the latest legislation and standards of practice.

Healthcare professionals should consult up-to-date Prescribing Information and the full Summary of Product Characteristics available from the manufacturers before prescribing any product. Medinews (Cardiology) Limited cannot accept responsibility for any errors in prescribing which may occur.